Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business ResultsGlobeNewsWire • Monday
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to NasdaqGlobeNewsWire • 10/15/24
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business ResultsGlobeNewsWire • 08/01/24
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic CystsGlobeNewsWire • 07/29/24
Interpace Biosciences Announces First Quarter 2024 Financial and Business ResultsGlobeNewsWire • 05/09/24
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business ResultsGlobeNewsWire • 03/07/24
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business ResultsGlobeNewsWire • 11/08/23
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business ResultsGlobeNewsWire • 08/09/23
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® ReimbursementGlobeNewsWire • 07/10/23
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023GlobeNewsWire • 06/05/23
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business ResultsGlobeNewsWire • 05/12/23
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business ResultsGlobeNewsWire • 03/27/23
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going ConcernGlobeNewsWire • 11/14/22
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual MeetingGlobeNewsWire • 10/20/22
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly ImprovedGlobeNewsWire • 09/01/22
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.GlobeNewsWire • 08/31/22
Interpace Biosciences Announces First Quarter 2022 Financial and Business ResultsGlobeNewsWire • 05/16/22
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business ResultsGlobeNewsWire • 03/31/22
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid TestsGlobeNewsWire • 01/29/22
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New DirectorGlobeNewsWire • 01/27/22
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights OfferingGlobeNewsWire • 01/12/22
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights OfferingGlobeNewsWire • 01/03/22
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity LoansGlobeNewsWire • 11/02/21
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related ConditionsGlobeNewsWire • 10/28/21
Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid NeoplasmsGlobeNewsWire • 10/21/21